Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.
Back
Examining the Feasibility of Surgery Omission After Neoadjuvant Systemic Therapy in Invasive Breast Cancer
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses lessons learned from a nonrandomized clinical trial evaluating selective elimination of surgery for invasive breast cancer.
Examining the Feasibility of Surgery Omission After Neoadjuvant Systemic Therapy in Invasive Breast Cancer
Episodes
All
All
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.
Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.
Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.
No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
5